Page 1 of 1

Daclizumab trial for relapsing-remitting MS begins

Posted: Mon May 24, 2010 5:25 am
by MSUK
Image

Active Comparator Study Designed to Examine the Safety and Efficacy of Daclizumab Formulated for Monthly Subcutaneous Dosing.

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to to interferon beta-1a (Avonex(R)) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).. [Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1502]

Posted: Mon May 24, 2010 8:39 am
by ssmme
It appears that this drug is to be taken monthly along with the weekly, every other day, or every three day interferon shots. It's a disappointment that it doesn't replace them.